https://orcid.org/0000-0001-7922-1209
References
- Olayioye MA , NeveRM , LaneHA , HynesNE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.19(13), 3159–3167 (2000).
- Lin Y , WangX , JinH. EGFR-TKI resistance in NSCLC patients--mechanisms and strategies. Am. J. Cancer Res.4(5), 411–435 (2014).
- Pao W , ChmieleckiJ. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer10(11), 760–774 (2010).
- Normanno N , DeLuca A , BiancoCet al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene366(1), 2–16 (2006).
- Meng Y , YuB , HuangHet al. Discovery of dosimertinib, a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung cancer. J. Med. Chem.64(2), 925–937 (2021).
- He P , NiuS , WangSet al. Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor. Acta Pharm. Sin. B9(6), 1193–1203 (2019).
- Herbst RS . Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys.59(Suppl. 2), 21–26 (2004).
- Tan D , YomS , TsaoMet al. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J. Thorac. Oncol.11(7), 946–963 (2016).
- Ye L , ChenX , ZhouF. EGFR-mutant NSCLC: emerging novel drugs. Curr. Opin. Oncol.33(1), 87–94 (2021).
- Yuan S , WangB , DaiQet al. Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors. J. Med. Chem.64(19), 14895–14911 (2021).
- Chen Y , YangL , QiaoHet al. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR (L858R/T790M) NSCLCs by the conformation constrained strategy. Eur. J. Med. Chem.199, 112388 (2020).
- Song Y , ZhaoM , ZhangH , YuB. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacol. Ther.107966 (2021).
- Tang K , JiaYN , YuB , LiuHM. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders. Eur. J. Med. Chem.204, 112657 (2020).
- Liu C , LuH , WangH , LooAet al. Combinations with allosteric shp2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clin. Cancer Res.27(1), 342–354 (2021).
- Sun Y , MeyersBA , CzakoBet al. Allosteric SHP2 Inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib. Cancer Res.80(21), 4840–4853 (2020).
- Song Y , YangX , YuB. Repurposing antidepressants for anticancer drug discovery. Drug Discov. TodayS1359-6446(21), 00475-X, https://doi.org/10.1016/j.drudis.2021.10.019 (2021).
- Song Y , ZhangH , YangX , ShiY , YuB. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021. Eur. J. Med. Chem.228, 114042 (2022).
- Lu Y , LiuY , OeckS , ZhangGJ , SchrammA , GlazerPM. Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway. Cancer Res.80(21), 4655–4667 (2020).
- Li Z , SuoF , HuBet al. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor. Bioorg. Chem.84, 164–169 (2019).
- Zheng M , HuoJ , GuXet al. Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP. J. Med. Chem.64(11), 7839–7852 (2021).